InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at Upcoming H.C. Wainwright Global Investment Conference
September 6, 2023
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, will be presenting at the 25th annual H.C. Wainwright Global Investment Conference. The conference is slated for Sept. 11–13, 2023, and will be held in New […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Shares Encouraging Results on Potential Cancer Treatment Approach
August 17, 2023
Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company today provided an interim analysis from its ongoing phase 1B trial of Next Generation Capecitabine (“NGC-Cap”) in patients with gastrointestinal cancer, which identifies a […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at Upcoming Sidoti & Co. Micro Cap Virtual Conference
August 11, 2023
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, will be presenting at this month’s Sidoti & Co. Micro Cap Virtual Conference. The two-day event is scheduled for Aug. 16–17, 2023. According to the announcement, […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces New Stage of Corporate Leadership
August 8, 2023
Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company today announced its appointment of industry veteran George Ng to serve as its chief executive officer and as a board director as of Aug. […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at MedInvest Oncology Conference
June 15, 2023
Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company has announced that its CEO David Young, Pharm.D., Ph.D. will present at the MedInvest Oncology Investor Conference taking place on June 21-22, 2023, […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Conduct NGC-Cap Trial Based on FDA Guidance and Project Optimus Oncology Initiative
May 18, 2023
Processa Pharmaceuticals (NASDAQ: PCSA) today announced its receipt of guidance from the U.S. Food and Drug Administration (“FDA”) regarding the company’s next trial for Next Generation Chemotherapy-Capecitabine (“NGC-Cap”). The phase 2 safety-efficacy trial will study a combination of PCS6422 and capecitabine for colorectal cancer patients following the principles of FDA’s Project Optimus Oncology Initiative, the […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Report on Gastroparesis Results at Annual Digestive Disease Meeting
April 28, 2023
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, will be presenting at the annual Digestive Disease Week (“DDW”) conference. The conference will be held on May 6–9, 2023, in Chicago. The company will be […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases FY 2022 Financials, Corporate Update
March 31, 2023
Processa Pharmaceuticals (NASDAQ: PCSA), a developer of next-generation chemotherapy drugs that provide a better safety-efficacy profile than widely used FDA-approved counterparts, is reporting on its full-year 2022 financial results and has also noted key accomplishments for the year. According to the announcement, PCSA will be focusing on the development of its next-generation chemotherapy drugs this […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Schedules Conference Call/Webinar to Review FY 2022 Results, Discuss Corporate Updates
March 23, 2023
Processa Pharmaceuticals (NASDAQ: PCSA), a developer of next-generation chemotherapy drugs that provide a better safety-efficacy profile than widely used FDA-approved counterparts, is hosting a conference call to discuss 2022 year-end results and company updates. The call, which will also be available through a live webcast, is slated to begin at 4:30 p.m. EST on March […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Doses First Patient in Key Study of Next-Generation Chemotherapy-Capecitabine
March 17, 2023
Processa Pharmaceuticals (NASDAQ: PCSA), a developer of next-generation chemotherapies (“NGCs”), has dosed the first patient in its NGC-Capecitabine (combination of PCS6422 and capecitabine) 300 mg dose group. This group is designed to obtain critical information on the drug exposure vs. adverse event relationship. The company noted that patients treated with next-generation chemotherapy-capecitabine have not had hand-foot syndrome or cardiotoxicity adverse events. “We […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Oppenheimer Healthcare Conference
March 7, 2023
Processa Pharmaceuticals (NASDAQ: PCSA), the developer of the next-generation chemotherapy drugs that will provide a better safety-efficacy profile than widely used FDA-approved counterparts, will be presenting at the 33rd annual Oppenheimer Healthcare Conference, held on March 14, 2023. According to the announcement, Processa Pharmaceuticals CEO and president Dr. David Young is scheduled for a virtual […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Prioritizes Development of Next Generation Chemotherapies
February 21, 2023
Processa Pharmaceuticals (NASDAQ: PCSA) today reiterates the strategic prioritization of its pipeline of proprietary oncology drugs, defined as Next Generation Chemotherapies (“NGCs”). According to the update, previous studies with these NGCs suggest potential improvement in the safety-efficacy profile, significantly differentiating these NGCs from their three presently widely used counterparts – capecitabine, gemcitabine and irinotecan. “The […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes on $6.25M Registered Direct Offering
February 15, 2023
Processa Pharmaceuticals (NASDAQ: PCSA), a diversified clinical-stage company developing next-generation chemotherapy drugs for patients who have unmet medical conditions and/or require better treatment options to improve a patient’s survival and/or quality of life, announced that it has closed on its registered direct offering. The company noted that the $6.25 million offering included definitive agreements with […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces $6.25M Registered Direct Offering
February 10, 2023
Processa Pharmaceuticals (NASDAQ: PCSA) is a diversified clinical-stage company developing next generation chemotherapy drugs for patients who have unmet medical conditions and/or require better treatment options to improve a patient’s survival and/or quality of life. The company today announced its entry into definitive agreements with retail investors for the purchase and sale of 7,812,544 common […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Biotech Showcase
January 4, 2023
Processa Pharmaceuticals (NASDAQ: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients with unmet medical need conditions, today announced that its CEO Dr. David Young will present an update on Processa’s future therapeutic focus and strategy at the upcoming Biotech Showcase. The presentation is scheduled to begin […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) PCS12852 Demonstrates Clinically Meaningful Improvements in Gastroparesis Symptoms
December 14, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients with unmet medical need conditions, today announced positive top-line results on the clinical symptoms associated with gastroparesis from a 4-week Phase 2A study of PCS12852. The randomized, dose-response study for the treatment of patients with […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) PCS12852 Demonstrates Improved Gastric Emptying in Phase 2A Trial
November 8, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need condition, today announced positive results from its PCS12852 Phase 2A trial in patients with moderate to severe gastroparesis. The four-week placebo-controlled, randomized, dose-response trial was designed to evaluate the […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q3 2022 Results, Provide Pipeline Update
November 2, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical need conditions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Nov. 8, 2022, to discuss its third quarter 2022 results and provide an […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Reports Successful Results from NGC Phase 2B Trial
November 1, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need conditions, is reporting positive results from its ongoing Next-Generation Capecitabine (“NGC”) phase 1B trial. According to the company, the trial indicates that NGC dosage regimens may have potential better […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Shares Update on Clinical Programs Enrollment
September 15, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage biopharmaceutical company focused on developing products to improve survival and/or quality of life for patients who have an unmet medical need condition for which there are few or no therapeutic options, has released update information regarding its clinical programs. Specifically, the updates provided information regarding enrollment for the […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at Upcoming Global Investment Conference
September 7, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition, will be part of the 22nd annual H.C. Wainwright Global Investment Conference. Processa Pharmaceuticals CEO Dr. David Young will be presenting at the event, which is scheduled […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Names New Key Board Appointments
August 16, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, has announced new board appointments. The company named Khoso Baluch and James Neal to its board of directors and appointed current board member Justin Yorke […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q2 2022 Results, Corporate Updates
August 12, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, is reporting financial numbers and clinical program updates for the quarter ended June 30, 2022. Highlights of the report include news that PCSA’s PCS12852 program is […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2022 Results Conference Call
August 8, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, has scheduled a conference call and webcast to discuss its second-quarter 2022 results; company executives will also provide an update on PCSA’s clinical pipeline during […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Launches New Website Focused on Rare Disease
August 4, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, has released a new website: Necrobiosislipoidicastudy.com. Through the new website, the company is working to increase awareness of ulcerative Necrobiosis Lipoidica (“uNL”), an extremely rare […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) CEO to Present at World Orphan Drug Congress USA
July 12, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have unmet medical conditions, has announced that its CEO Dr. David Young will present at the World Orphan Drug Congress USA 2022 Conference. Dr. Young’s presentation, “Thinking Regulatory First – Considerations for the Effective […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q1 2022 Report, Updates
May 13, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, is reporting its financial results for the quarter ended March 31, 2022; the company also released an update on its clinical programs. According to the […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q1 2022 Results, Provide Drug Development Update
May 5, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on May 12, 2022, to discuss its results for the first quarter and provide an […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Administers First Dosage in Amended Phase 1B Study
April 20, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, has started its amended maximum-tolerated dose (“MTD”) phase 1B trial for Next Generation Capecitabine, or the combination of PCS6422 and capecitabine. The company announced that the first patient, who […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Enrolls First Patient in PCS12852 Phase 2A Trial
April 5, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it has enrolled its first patient in the Phase 2A clinical trial of PCS12852 in patients with moderate to severe gastroparesis. A chronic gastric motility disorder in which […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Year-End 2021 Financial, Corporate Results
March 31, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve survival and/or quality of life, has reported its financial numbers and corporate highlights for 2021 year end. Highlights of the report included the success of the company’s next-generation capecitabine Phase 1B […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q4 2021 Results, Provide Clinical Pipeline Update
March 23, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical need conditions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on March 30, 2022, to discuss its fourth quarter 2021 results and provide an […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) CEO to Present at Oppenheimer 32nd Annual Healthcare Conference
March 10, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical need conditions, today announced that its CEO Dr. David Young will present at the Oppenheimer 32nd Annual Healthcare Conference. Dr. Young’s presentation is slated to begin at 10:00 a.m. Eastern Time on […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Issues Letter to Shareholders Eyeing ‘Transformative Year’ in 2022
January 26, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today released a letter to shareholders from its Chief Executive Officer Dr. David Young. In the letter, Dr. Young shared 2021 accomplishments and the company’s […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q3 2021 Financial, Corporate Results
November 12, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve survival and/or quality of life, has reported its financial numbers and corporate highlights for third quarter 2021. Included in the report was results of the company’s next-generation capecitabine phase 1B trial, […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Results of Next-Generation Capecitabine Analysis
November 4, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has released information regarding its next-generation capecitabine study. According to the company, the next-generation capecitabine dosage regimen, which is a combination of PCS6422 administered with capecitabine, successfully inhibited dihydropyrimidine dehydrogenase […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Q3 Results, Development Update Call
October 26, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it will report financial results for the quarter ended Sept. 30, 2021, on Thursday, Nov. 11, 2021. According to the update, the company will host a conference call […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Key Milestone in Clinical Develop Program for PCS12852
October 12, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it has been cleared by the U.S. Food and Drug Administration (“FDA”) to proceed with a phase 2a clinical trial of PCS12852. The trial will study PCS12852 in […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Investor Conferences
September 16, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that management will participate in upcoming investor conferences. According to the update, PCSA will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit starting at 9:05 a.m. […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at World Orphan Drug Congress USA
August 24, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, will be presenting at the World Orphan Drug Congress USA Conference. The three-day event is scheduled for Aug. 25-27. Processa CEO and chair Dr. David Young will be the company […]